Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Key Product Details
Validated by
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Leu16-Ala539
Accession # P54761
Specificity
Clonality
Host
Isotype
Scientific Data Images for Mouse EphB4 Antibody
EphB4 in Mouse Embryo.
EphB4 was detected in immersion fixed frozen sections of mouse embryo (15 d.p.c.) using Goat Anti-Mouse EphB4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF446) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.Detection of Mouse EphB4 by Western Blot
Reduced Eph-B4 activity increases venous neointimal thickening. (A) Representative photomicrographs (left panel) and bar graph (right panel) showing AVF venous limb wall thickness in control and Eph-B4 het mice (day 21); *P = 0.047 (t-test). n = 8. Scale bar 25 µm. (B) Line graph showing infrarenal IVC diameter in control or Eph-B4 het mice; *P = 0.59 (ANOVA). n = 8–9. (C) Representative Western blot showing inhibited tyrosine phosphorylation in the Y774F-Eph-B4 mutant compared to the WT-Eph-B4 construct (0–60 min). (D) Bar graph showing Ephrin-B2/Fc stimulated COS cell migration after transfection with WT-Eph-B4 or Y774F-Eph-B4 plasmids. P < 0.0001 (ANOVA); *P < 0.0001 Ephrin-B2/Fc WT-Eph-B4 vs Y774F-Eph-B4. n = 3–4. (E) Representative photomicrographs (left panel) showing AVF venous wall (elastin stain) in control mice or mice treated with WT-Eph-B4 or mutant Y774F-Eph-B4. Arrow heads denote neointimal thickness. Scale bar, 25 µm. Bar graph (right panel) showing quantification of AVF venous wall thickness in control mice (white bar) or mice treated with WT-Eph-B4 (gray bar) or mutant Y774F-Eph-B4 (blue bar), day 21; P = 0.035 (ANOVA). *P = 0.038 (WT-Eph-B4 vs Y774F-Eph-B4; post hoc). n = 5–7. (F) Line graph showing infrarenal IVC diameter in mice with AVF treated with WT-Eph-B4 (gray line) or mutant Y774F-Eph-B4 (purple line) compared to control (black line); *P = 0.005 (ANOVA). n = 5–11. Data represent mean ± SEM. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29133876), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Human EphB4 by Western Blot
Increased Eph-B4 and Ephrin-B2 expression during adaptive venous remodeling. (A) Western blot and adjacent bar graph of densitometry showing human Eph-B4 expression in AVF venous limb compared to normal vein. *P = 0.0016; t-test. n = 3–4. (B) Line graphs show expression of Eph-B4 (blue) and Ephrin-B2 (red) in the AVF venous limb compared to sham IVC; P < 0.0001 (ANOVA). *P < 0.05 (P = 0.0123, Eph-B4; P = 0.0041, Ephrin-B2; post hoc); **P < 0.05 (P < 0.0001, Ephrin-B2; post hoc). n = 5–8. (C) Western blots showing Eph-B4 and Ephrin-B2 protein expression in AVF venous limb compared to sham IVC. n = 3–5. (D) Graphs showing densitometry of Eph-B4 (left panel) and Ephrin-B2 (right panel) expression in the AVF venous limb compared to sham IVC; *P < 0.05 (P < 0.0001, Eph-B4 day 7, AVF vs sham; P < 0.0001, Eph-B4 day 21, AVF vs sham; P < 0.0001, Ephrin-B2 day 7, AVF vs sham; post hoc). n = 3–5. (E) Diagram of rat model showing location of infrarenal IVC pericardial patch exposed to an aortocaval AVF (n = 6 per group). (F) Representative Western blot (upper panel) showing Eph-B4 and Ephrin-B2 expression in patch neointima (day 14) of control vein compared to patch neointima of AVF vein. Graphs (lower panel) show quantification of western blot bands; P < 0.0001 (ANOVA). *P < 0.05 (P = 0.0003, Eph-B4; P = 0.0043, Ephrin-B2; post hoc). n = 3. (G) Representative photomicrographs (upper panel) showing Eph-B4 (green) and Ephrin-B2 (red) immunoreactive signal (day 14). White arrowheads indicate colocalization of Eph-B4 and Ephrin-B2. L, vessel lumen. Graph (lower panel) shows quantification of immunoreactive signal; P < 0.0001 (ANOVA). *P < 0.05 (P = 0.0136 Eph-B4; P < 0.0001 Ephrin-B2; post hoc). n = 3. Scale bar 100 µm. Data represent mean ± SEM. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29133876), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Human EphB4 by Western Blot
Increased Eph-B4 and Ephrin-B2 expression during adaptive venous remodeling. (A) Western blot and adjacent bar graph of densitometry showing human Eph-B4 expression in AVF venous limb compared to normal vein. *P = 0.0016; t-test. n = 3–4. (B) Line graphs show expression of Eph-B4 (blue) and Ephrin-B2 (red) in the AVF venous limb compared to sham IVC; P < 0.0001 (ANOVA). *P < 0.05 (P = 0.0123, Eph-B4; P = 0.0041, Ephrin-B2; post hoc); **P < 0.05 (P < 0.0001, Ephrin-B2; post hoc). n = 5–8. (C) Western blots showing Eph-B4 and Ephrin-B2 protein expression in AVF venous limb compared to sham IVC. n = 3–5. (D) Graphs showing densitometry of Eph-B4 (left panel) and Ephrin-B2 (right panel) expression in the AVF venous limb compared to sham IVC; *P < 0.05 (P < 0.0001, Eph-B4 day 7, AVF vs sham; P < 0.0001, Eph-B4 day 21, AVF vs sham; P < 0.0001, Ephrin-B2 day 7, AVF vs sham; post hoc). n = 3–5. (E) Diagram of rat model showing location of infrarenal IVC pericardial patch exposed to an aortocaval AVF (n = 6 per group). (F) Representative Western blot (upper panel) showing Eph-B4 and Ephrin-B2 expression in patch neointima (day 14) of control vein compared to patch neointima of AVF vein. Graphs (lower panel) show quantification of western blot bands; P < 0.0001 (ANOVA). *P < 0.05 (P = 0.0003, Eph-B4; P = 0.0043, Ephrin-B2; post hoc). n = 3. (G) Representative photomicrographs (upper panel) showing Eph-B4 (green) and Ephrin-B2 (red) immunoreactive signal (day 14). White arrowheads indicate colocalization of Eph-B4 and Ephrin-B2. L, vessel lumen. Graph (lower panel) shows quantification of immunoreactive signal; P < 0.0001 (ANOVA). *P < 0.05 (P = 0.0136 Eph-B4; P < 0.0001 Ephrin-B2; post hoc). n = 3. Scale bar 100 µm. Data represent mean ± SEM. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29133876), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of EphB4 by Immunohistochemistry
Immunofluorescent analysis of vascular networks in the pituitary posterior lobe. (A-C) Immunofluorescent analysis for Isolectin B4 (red) (A, B and C), Dll4 (green) (A), EphB2 (green) (B), EphB4 (green) (B), Notch4 (green) (C) and PLVAP (blue) (A). Larger radius vessels strongly labeled with Isolectin B4 are Dll4-positive (arrows) and PLVAP-negative (arrow heads) (A), EphB2-negative (arrow heads) and EphB4-negative (arrow heads) (B). (C) shows that Notch4 expressed in Isolectin B4-positive vessels in the pituitary posterior lobe but not in Notch4 KO mice. Scale bars = 50 μm (A, B and C). Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41598-025-17225-5), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of EphB4 by Immunohistochemistry
EphB4 signaling in PF.(A and B) Human IPF lung fibroblasts were treated with TGF-beta 1 or PBS for 24 hours. Cells (total 16 samples; n = 4 patients/group) were then treated with either NVP-BHG712 (250 nM) (A) or Ephb4 siRNA (B), or their respective controls, for an additional 24 hours. Protein lysates were collected, and Western blotting was performed to detect ELN protein levels. ImageJ densitometry was performed and normalized to GAPDH (mean ± SD). *P < 0.05; **P < 0.01, as determined by paired 2-way ANOVA followed by Tukey’s post hoc test adjusted for multiple comparisons. (C) Western blotting of siRNA treated IPF cells to detect P-SMAD 2/3 and total SMAD 2/3 (n = 4/group). (D and E) Verhoeff Van Gieson staining was performed on lung sections from mice with Ephb4 conditional knockout or respective control mice to visualize ELN (n = 5/group) following bleomycin or PBS instillation (D), or mice with bleomycin or PBS instillation treated with EphB4 inhibitor NVP-BHG712 (10 mg/kg) or vehicle (n = 5/group) (E). ELN staining was semiquantitatively scored (scores 0–3). ****P < 0.0001 as determined by 2-way ANOVA followed by Tukey’s post hoc tests adjusted for multiple comparisons. (F) Schematic depicting the role of EphB4 signaling in PF. Image collected and cropped by CiteAb from the following open publication (https://insight.jci.org/articles/view/189156), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of EphB4 by Western Blot
Preserved protein stability with compromised tyrosine kinase activity in EPHB4 kinase domain variants.a Steady-state abundance of EPHB4 D-mis mutants. Cos-7 cells were transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants together with an eGFP-encoding vector. Numbers at top indicate percentage of GFP+ cells determined by flow cytometry (see Supplementary Fig. 3). Cells were lysed and EPHB4 abundance determined by Western blot for c-myc (left) or EPHB4 (right). Blots were probed for tubulin or beta actin (ActB) respectively to demonstrate equivalent protein loading. Numbers below indicate normalized abundance of EPHB4 D-mis mutants relative to WT EPHB4. Each experiment was repeated two times with similar results. b Stability of EPHB4 D-mis mutants. Cos-7 cells transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants were treated with cycloheximide (CHX) for the indicated times before lysis and determination of EPHB4 and ActB abundance by Western blot. Numbers indicate normalized EPHB4 abundance relative to CHX-untreated cells for each time point. Shown are the results of a single experiment. c Kinase activity of EPHB4 D-mis mutants. EPHB4 was immunoprecipitated from Cos-7 cells transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants. EPHB4 kinase activity was determined by Western blot of immunoprecipitates with an anti-phosphotyrosine antibody (pTyr). Numbers indicate normalized pTyr content of EPHB4 D-mis mutants relative to WT EPHB4. Shown are the results of one experiment of two repeats. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37978175), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of EphB4 by Western Blot
Preserved protein stability with compromised tyrosine kinase activity in EPHB4 kinase domain variants.a Steady-state abundance of EPHB4 D-mis mutants. Cos-7 cells were transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants together with an eGFP-encoding vector. Numbers at top indicate percentage of GFP+ cells determined by flow cytometry (see Supplementary Fig. 3). Cells were lysed and EPHB4 abundance determined by Western blot for c-myc (left) or EPHB4 (right). Blots were probed for tubulin or beta actin (ActB) respectively to demonstrate equivalent protein loading. Numbers below indicate normalized abundance of EPHB4 D-mis mutants relative to WT EPHB4. Each experiment was repeated two times with similar results. b Stability of EPHB4 D-mis mutants. Cos-7 cells transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants were treated with cycloheximide (CHX) for the indicated times before lysis and determination of EPHB4 and ActB abundance by Western blot. Numbers indicate normalized EPHB4 abundance relative to CHX-untreated cells for each time point. Shown are the results of a single experiment. c Kinase activity of EPHB4 D-mis mutants. EPHB4 was immunoprecipitated from Cos-7 cells transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants. EPHB4 kinase activity was determined by Western blot of immunoprecipitates with an anti-phosphotyrosine antibody (pTyr). Numbers indicate normalized pTyr content of EPHB4 D-mis mutants relative to WT EPHB4. Shown are the results of one experiment of two repeats. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37978175), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of EphB4 by Western Blot
Preserved protein stability with compromised tyrosine kinase activity in EPHB4 kinase domain variants.a Steady-state abundance of EPHB4 D-mis mutants. Cos-7 cells were transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants together with an eGFP-encoding vector. Numbers at top indicate percentage of GFP+ cells determined by flow cytometry (see Supplementary Fig. 3). Cells were lysed and EPHB4 abundance determined by Western blot for c-myc (left) or EPHB4 (right). Blots were probed for tubulin or beta actin (ActB) respectively to demonstrate equivalent protein loading. Numbers below indicate normalized abundance of EPHB4 D-mis mutants relative to WT EPHB4. Each experiment was repeated two times with similar results. b Stability of EPHB4 D-mis mutants. Cos-7 cells transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants were treated with cycloheximide (CHX) for the indicated times before lysis and determination of EPHB4 and ActB abundance by Western blot. Numbers indicate normalized EPHB4 abundance relative to CHX-untreated cells for each time point. Shown are the results of a single experiment. c Kinase activity of EPHB4 D-mis mutants. EPHB4 was immunoprecipitated from Cos-7 cells transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants. EPHB4 kinase activity was determined by Western blot of immunoprecipitates with an anti-phosphotyrosine antibody (pTyr). Numbers indicate normalized pTyr content of EPHB4 D-mis mutants relative to WT EPHB4. Shown are the results of one experiment of two repeats. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37978175), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of EphB4 by Western Blot
Interplay of EphB4, ephrin-B2 and SoxF factors.a–d Confocal images and quantitation of Sox17 immunostaining in retinal sprouts (b) and artery (b, d) (n = 5 control and 5 Ephb4i delta EC and n = 5 control and 5 Efnb2i delta EC) and percentage of cells with high Sox17 immunosignal vs total ECs (n = 3 control and 3 Ephb4i delta EC and n = 3 control and 3 Efnb2i delta EC) (b, d). e Violin plots of SOX7, SOX17 and SOX18 gene expression from scRNA-seq experiment comparing siControl and siEPHB4 cells. f SoxF factors reduce EPHB4 and increase EFNB2 transcripts (n = 3 experiments). g, h Immunoblot analysis and quantitation of EphB4 and ephrin-B2 protein upon SOX7 + SOX17 + SOX18 knockdown (n = 3 experiments). i Genome localization of Sox18 putative motifs in EFNB2 and EPHB4 human genes selected for further investigation. j Quantitation graphs for luciferase activity of putative binding regions of Sox18 on EFNB2 and EPHB4 showing direct regulation of EFNB2 expression via Sox18 in two regions (n = 3 experiments). k Increased luciferase activity upon EPHB4 KD compared to siControl for Sox18 binding regions on EFNB2 (n = 3 experiments). l Sox17 expression in ephrin-B2+ sprouts (single confocal z-plane). IB4, GFP and Sox17 staining in P6 Efnb2-H2B-GFP knock-in reporter retinal vasculature. m Graph indicating proportion of Sox17+ cells in ephrin-B2+ tip cells (n = 3 Efnb2-GFP mice). n Schematic representation of interactions between Sox17, ephrin-B2 and EphB4. P values were calculated using two-tailed unpaired t test (b, d, f, h) and one-way ANOVA (j,k). In vivo experiments were performed with tamoxifen injections at P1-P3 and analysis at P6 (a, c). Data are presented as mean values ± SEM. Source data are provided as a Source Data file. Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41467-024-46300-0), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of EphB4 by Immunohistochemistry
VOGM-specific EPHB4 variant disrupts developmental angiogenesis.Ephb4+/F867L mice were intercrossed. a Number of live born Ephb4+/+ wild-type (WT), Ephb4+/F867L heterozygote (Het), and Ephb4F867L/F867L homozygote (Hom) mice. **p = 0.0046; Chi-squared test (two-sided). b Images of littermate embryos of the indicated genotypes at E10.5. Note abnormal vascularization of the yolk sac, reduced size and distended pericardial sac (arrow) of homozygous Ephb4F867L/F867L embryos. c Mean +/- 1 SEM of embryo length at E10.5 (WT, n = 10; Het, n = 18; Hom, n = 8). ****P < 0.0001; ns, not significant; Student’s two-sample two-sided t-test. d E10.5 yolk sacs were stained with anti-CD31 antibodies to identify vasculature. Images at right are higher magnifications of the boxed areas of images at left. Note hierarchical vascular networks in yolk sacs of wild-type and heterozygous embryos and primitive vascular plexuses in yolk sacs of homozygous Ephb4F867L/F867L embryos that present as classical honeycomb-like structures at higher magnification. e CD31 antibody staining of E9.5 embryos of the indicated genotypes. For each embryo, the right image is a higher magnification of the boxed area in the left image. Arrows show trunk angiogenesis toward the midline in wild-type and heterozygous embryos but not homozygous Ephb4F867L/F867L embryos. Images in (d, e) are representative of at least 2 embryos of each genotype. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37978175), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of EphB4 by Immunohistochemistry
Ephrin-B2 and EphB4 regulate EC segregation and artery formation.a Homotypic or heterotypic co-culture of HUVECs and HUAECs, as indicated. Final snapshots of CellTracker-labeled cells imaged for 48 h after removal of Ibidi insert. Quantitation graph for relative border length (n = 3 experiments). b RT-qPCR for EPHB4 and EFNB2 in HUVECs and HUAECs (n = 3 experiments). c, d EphB4 restrains while ephrin-B2 promotes artery growth. High-magnification confocal images of IB4 and GFP stained P6 retinal vasculature (n = 6 control and Ephb4i delta TC mice (c) and n = 6 control and 4 Efnb2i delta TC mice (d)). e, f Quantitation of the GFP+ area (Esm1-derived progeny) in capillary plexus, front and artery per total GFP positive area (n = 6 control and Ephb4i delta TC mice (e) and n = 6 control and 4 Efnb2i delta TC mice (f )). g, h Arteries in Ephb4i delta TC mice are longer and have more branches, while both parameters are reduced in Efnb2i delta TC mice. Graphs show number of arterial branches and artery extension relative to vascular plexus extension (n = 9 control and 8 Ephb4i delta TC mice (g) and n = 6 control and 4 Efnb2i delta TC mice (h)). i Representative images of Ephb4i delta TC retinas with arterial alterations compared to control. Graph shows quantitation of AV retinal crossings, overextended arterial side branches and normal vascular morphology (n = 17 control and 17 Ephb4i delta TC). j Scheme depicting that ephrin-B2-EphB4 interaction and correct levels are required for proper artery formation. P values were calculated by one-way ANOVA (a), two-tailed unpaired t test (b–h) and Chi-square test (i). In vivo experiments were performed with tamoxifen injections from P1-P3 with analysis at P6 (c, d, g–i). Data are presented as mean values ± SEM. Source data are provided as a Source Data file. Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41467-024-46300-0), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Mouse EphB4 Antibody
CyTOF-ready
Flow Cytometry
Sample: MCF‑7 human breast cancer cell line
Immunohistochemistry
Sample: Immersion fixed frozen sections of mouse embryo (E13-15)
Western Blot
Sample: Recombinant Mouse EphB4 Fc Chimera (Catalog # 446-B4)
Reviewed Applications
Read 4 reviews rated 4.3 using AF446 in the following applications:
Flow Cytometry Panel Builder
Bio-Techne Knows Flow Cytometry
Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.
Advanced Features
- Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
- Spillover Popups - Visualize the spectra of individual fluorochromes
- Antigen Density Selector - Match fluorochrome brightness with antigen density
Formulation, Preparation, and Storage
Purification
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Calculators
Background: EphB4
References
- Eph Nomenclature Committee [letter] (1997) Cell 90:403.
- Flanagan, J.G. and P. Vanderhaeghen (1998) Annu. Rev. Neurosci. 21:309.
- Pasquale, E.B. (1997) Curr. Opin. Cell Biol. 9:608.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional EphB4 Products
Product Documents for Mouse EphB4 Antibody
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Note: Certificate of Analysis not available for kit components.
Product Specific Notices for Mouse EphB4 Antibody
For research use only
Related Research Areas
Citations for Mouse EphB4 Antibody
Customer Reviews for Mouse EphB4 Antibody (4)
Have you used Mouse EphB4 Antibody?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 for a review with an image
$10/€7/£6/$10CAN/¥1110 for a review without an image
Submit a review
Customer Images
-
Application: Immunocytochemistry/ImmunofluorescenceSample Tested: E12.5 mouse embryo fixed in 4% PFASpecies: MouseVerified Customer | Posted 12/16/2020Dilution used - 1:200. The staining was done on an E12.5 transverse (4% PFA fixed) mouse section using standard IF techniques. Used 1% BSA for blocking for 1 hour before adding the primary antibody. The results are hit or miss for me, because I have noticed expression on non target tissue (Sometimes it doesn't appear, sometimes it does). Attached pictures shows a artery (smaller circle) and a vein (bigger circle), and while the EphB4 expression on the vein is very good (as it is supposed to express there), there seems to be some non-specific expression on the adjacent artery as well.
-
Application: Western BlotSample Tested: embryosSpecies: ZebrafishVerified Customer | Posted 11/13/2020
-
Application: Western BlotSample Tested: See PMID 22398409Species: RatVerified Customer | Posted 01/08/2015
-
Application: ImmunofluorescenceSample Tested: See PMID 22398409Species: RatVerified Customer | Posted 01/08/2015
There are no reviews that match your criteria.
Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
- 7-Amino Actinomycin D (7-AAD) Cell Viability Flow Cytometry Protocol
- Antigen Retrieval Protocol (PIER)
- Antigen Retrieval for Frozen Sections Protocol
- Appropriate Fixation of IHC/ICC Samples
- Cellular Response to Hypoxia Protocols
- Chromogenic IHC Staining of Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Protocol
- Chromogenic Immunohistochemistry Staining of Frozen Tissue
- ClariTSA™ Fluorophore Kits
- Detection & Visualization of Antibody Binding
- Extracellular Membrane Flow Cytometry Protocol
- Flow Cytometry Protocol for Cell Surface Markers
- Flow Cytometry Protocol for Staining Membrane Associated Proteins
- Flow Cytometry Staining Protocols
- Flow Cytometry Troubleshooting Guide
- Fluorescent IHC Staining of Frozen Tissue Protocol
- Graphic Protocol for Heat-induced Epitope Retrieval
- Graphic Protocol for the Preparation and Fluorescent IHC Staining of Frozen Tissue Sections
- Graphic Protocol for the Preparation and Fluorescent IHC Staining of Paraffin-embedded Tissue Sections
- Graphic Protocol for the Preparation of Gelatin-coated Slides for Histological Tissue Sections
- IHC Sample Preparation (Frozen sections vs Paraffin)
- Immunofluorescent IHC Staining of Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Protocol
- Immunohistochemistry (IHC) and Immunocytochemistry (ICC) Protocols
- Immunohistochemistry Frozen Troubleshooting
- Immunohistochemistry Paraffin Troubleshooting
- Intracellular Flow Cytometry Protocol Using Alcohol (Methanol)
- Intracellular Flow Cytometry Protocol Using Detergents
- Intracellular Nuclear Staining Flow Cytometry Protocol Using Detergents
- Intracellular Staining Flow Cytometry Protocol Using Alcohol Permeabilization
- Intracellular Staining Flow Cytometry Protocol Using Detergents to Permeabilize Cells
- Preparing Samples for IHC/ICC Experiments
- Preventing Non-Specific Staining (Non-Specific Binding)
- Primary Antibody Selection & Optimization
- Propidium Iodide Cell Viability Flow Cytometry Protocol
- Protocol for Heat-Induced Epitope Retrieval (HIER)
- Protocol for Liperfluo
- Protocol for Making a 4% Formaldehyde Solution in PBS
- Protocol for VisUCyte™ HRP Polymer Detection Reagent
- Protocol for the Characterization of Human Th22 Cells
- Protocol for the Characterization of Human Th9 Cells
- Protocol for the Preparation & Fixation of Cells on Coverslips
- Protocol for the Preparation and Chromogenic IHC Staining of Frozen Tissue Sections
- Protocol for the Preparation and Chromogenic IHC Staining of Frozen Tissue Sections - Graphic
- Protocol for the Preparation and Chromogenic IHC Staining of Paraffin-embedded Tissue Sections
- Protocol for the Preparation and Chromogenic IHC Staining of Paraffin-embedded Tissue Sections - Graphic
- Protocol for the Preparation and Fluorescent IHC Staining of Frozen Tissue Sections
- Protocol for the Preparation and Fluorescent IHC Staining of Paraffin-embedded Tissue Sections
- Protocol for the Preparation of Gelatin-coated Slides for Histological Tissue Sections
- Protocol: Annexin V and PI Staining by Flow Cytometry
- Protocol: Annexin V and PI Staining for Apoptosis by Flow Cytometry
- R&D Systems Quality Control Western Blot Protocol
- TUNEL and Active Caspase-3 Detection by IHC/ICC Protocol
- The Importance of IHC/ICC Controls
- Troubleshooting Guide: Fluorokine Flow Cytometry Kits
- Troubleshooting Guide: Immunohistochemistry
- Troubleshooting Guide: Western Blot Figures
- Western Blot Conditions
- Western Blot Protocol
- Western Blot Protocol for Cell Lysates
- Western Blot Troubleshooting
- Western Blot Troubleshooting Guide
- View all Protocols, Troubleshooting, Illustrated assays and Webinars